Systematic Review of Anti-Tumor Necrosis Factor-alpha Therapy for Treatment of Immune-mediated Uveitis

REFERENCES

• Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology. Mar 2004;111(3):491–500; discussion 500.
   Google Scholar
• Wakefield D, Chang JH. Epidemiology of uveitis. Int Ophthalmol Clin. Spring 2005;45(2):1–13.
   Google Scholar
• Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet’s disease. Lancet. Jul 28 2001;358(9278):295–296.
   PubMed Web of Science ®Google Scholar
• Oxford Centre for Evidence-based Medicine. Levels of evidence. BJU Int. Mar 2009;104(11):1825.
   Google Scholar
• Harper SL, Chorich, LJ, Foster, CS. Diagnosis of uveitis. In: Vitale A, ed. Diagnosis and Treatment of Uveitis. Philadelphia: WB Sanders; 2002:79–97.
   Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol. 2005 Sep;140(3):509–516.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. Apr 1985;92(4):467–471.
   Google Scholar
• Nussenblatt RB, Whitcup, SM, Palestine, A.G. Uveitis: fundamentals and clinical practice. In: Nussenblatt RB, Whitcup SM, Palestine AG, eds. Examination of the Patient with Uveitis. St. Louis: Mosby; 1996:58–68.
   Google Scholar
• Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. Mar 2007;91(3):319–324.
   PubMed Web of Science ®Google Scholar
• Rao NA, Forster DJ, Spalton DJ. The uvea: uveitis and intraocular neoplasms. In: Podos SM, Yanoff M, eds. Anterior uveitis, vol 2. New York: Gower Medical; 1992:1–19.
   Google Scholar
• Forrester JV, Ben Ezra D, Nussenblatt RB, Tabbara KF, Timonen P. Grading of intermediate, posterior uveitis. In: Tabbara KF, Nussenblatt RB, eds. Posterior Uveitis: Diagnosis and Management. Boston: Butterworth-Heinemann; 1994:5–18.
   Google Scholar
• Rudwaleit M, Rodevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. May 2009;68(5):696–701.
   PubMed Web of Science ®Google Scholar
• Diaz-Llopis M, Garcia-Delpech S, Salom D, et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther. Jun 2008;24(3):351–361.
   PubMed Web of Science ®Google Scholar
• Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Behcet disease. Ocul Immunol Inflamm. Jun 2010;18(3):226–232.
   Google Scholar
• Callejas-Rubio JL, Sanchez-Cano D, Serrano JL, Ortego-Centeno N. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther. Dec 2008;24(6):613–614; author reply 614.
   Google Scholar
• Calvo Catala J, Campos Fernandez C, Rueda Cid A, Gonzalez-Cruz Cervellera MI, Baixauli Rubio A, Pastor Cubillo MD. Efficacy of adalimumab in Behcet’s disease: description of 6 cases. Reumatol Clin. Jul-Aug 2011;7(4):258–261.
   Google Scholar
• Dhingra N, Morgan J, Dick AD. Switching biologic agents for uveitis. Eye (Lond). Sep 2009;23(9):1868–1870.
   Google Scholar
• Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behcet’s disease. Eye (Lond). Jun 2007;21(6):824–825.
   PubMed Web of Science ®Google Scholar
• Trachana M, Pratsidou-Gertsi P, Pardalos G, Kozeis N, Badouraki M, Kanakoudi-Tsakalidou F. Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis. Scand J Rheumatol. Mar 2011;40(2):101–107.
   Google Scholar
• Tynjala P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford). Mar 2008;47(3):339–344.
   PubMed Web of Science ®Google Scholar
• Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr. Oct 2006;149(4):572–575.
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Nielsen S, Kummerle-Deschner J, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol. May 2007;34(5):1146–1150.
   PubMedGoogle Scholar
• Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken). Apr 2011;63(4):612–618.
   Google Scholar
• Huynh N, Cervantes-Castaneda RA, Bhat P, Gallagher MJ, Foster CS. Biologic response modifier therapy for psoriatic ocular inflammatory disease. Ocul Immunol Inflamm. May-Jun 2008;16(3):89–93.
   PubMed Web of Science ®Google Scholar
• Petropoulos IK, Vaudaux JD, Guex-Crosier Y. Anti-TNF-alpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital. Klin Monbl Augenheilkd. May 2008;225(5):457–461.
   Google Scholar
• Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis. Dec 2006;65(12):1631–1634.
   PubMed Web of Science ®Google Scholar
• Gallagher M, Quinones K, Cervantes-Castaneda RA, Yilmaz T, Foster CS. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol. Oct 2007;91(10):1341–1344.
   PubMed Web of Science ®Google Scholar
• Al-Rayes H, Al-Swailem R, Al-Balawi M, Al-Dohayan N, Al-Zaidi S, Tariq M. Safety and efficacy of infliximab therapy in active behcet’s uveitis: an open-label trial. Rheumatol Int. Nov 2008;29(1):53–57.
   PubMed Web of Science ®Google Scholar
• Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet’s disease with refractory uveoretinitis. J Rheumatol. Jul 2004;31(7):1362–1368.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Smith JR, Giles TR, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol. Jun 2009;127(6):819–822.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. Jul 2005;123(7):903–912.
   Google Scholar
• Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behcet’s disease. Int Ophthalmol. Jun 2005;26(3):83–92.
   PubMedGoogle Scholar
• Accorinti M, Pirraglia MP, Paroli MP, Priori R, Conti F, Pivetti-Pezzi P. Infliximab treatment for ocular and extraocular manifestations of Behcet’s disease. Jpn J Ophthalmol. May-Jun 2007;51(3):191–196.
   PubMed Web of Science ®Google Scholar
• Arayssi T, Hamra R, Homeidan F, et al. The efficacy of a single dose of infliximab in the treatment of Behcet’s disease uveitis. Clin Exp Rheumatol. May-Jun 2005;23(3):427.
   Google Scholar
• Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E, et al. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye (Lond). Aug 2005;19(8):841–845.
   Google Scholar
• Joseph A, Raj D, Dua HS, Powell PT, Lanyon PC, Powell RJ. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology. Jul 2003;110(7):1449–1453.
   PubMed Web of Science ®Google Scholar
• Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol. May 2005;89(5):533–536.
   Google Scholar
• Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol. Oct 2004;138(4):648–650.
   Google Scholar
• Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet’s disease: a 24-month follow-up study. Rheumatology (Oxford). Jul 2007;46(7):1161–1164.
   PubMed Web of Science ®Google Scholar
• Niccoli L, Nannini C, Cassara E, Gini G, Lenzetti I, Cantini F. Efficacy of infliximab therapy in two patients with refractory Vogt-Koyanagi-Harada disease. Br J Ophthalmol. Nov 2009;93(11):1553–1554.
   Google Scholar
• Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med. Mar 2 2004;140(5):404–406.
   PubMed Web of Science ®Google Scholar
• Sugita S, Yamada Y, Kaneko S, Horie S, Mochizuki M. Induction of regulatory T cells by infliximab in Behcet’s disease. Invest Ophthalmol Vis Sci. Jan 2011;52(1):476–484.
   Google Scholar
• Sugita S, Yamada Y, Mochizuki M. Relationship between serum infliximab levels and acute uveitis attacks in patients with Behcet disease. Br J Ophthalmol. Apr 2011;95(4):549–552.
   Google Scholar
• Tugal-Tutkun I, Ayranci O, Kasapcopur O, Kir N. Retrospective analysis of children with uveitis treated with infliximab. J AAPOS. Dec 2008;12(6):611–613.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet’s disease: an open-label trial. Arthritis Rheum. Aug 2005;52(8):2478–2484.
   PubMedGoogle Scholar
• Adan A, Hernandez V, Ortiz S, et al. Effects of infliximab in the treatment of refractory posterior uveitis of Behcet’s disease after withdrawal of infusions. Int Ophthalmol. Oct 2010;30(5):577–581.
   PubMedGoogle Scholar
• Ardoin SP, Kredich D, Rabinovich E, Schanberg LE, Jaffe GJ. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol. Dec 2007;144(6):844–849.
   PubMed Web of Science ®Google Scholar
• Bodaghi B, Bui Quoc E, Wechsler B, et al. Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors. Ann Rheum Dis. Jun 2005;64(6):962–964.
   Google Scholar
• El-Shabrawi Y, Hermann J. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology. Dec 2002;109(12):2342–2346.
   Google Scholar
• Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. May 2006;113(5):860–864 e862.
   Google Scholar
• Khalifa YM, Bailony MR, Acharya NR. Treatment of pediatric vogt-koyanagi-harada syndrome with infliximab. Ocul Immunol Inflamm. Jun 2010;18(3):218–222.
   PubMed Web of Science ®Google Scholar
• Lanthier N, Parc C, Scavennec R, Dhote R, Brezin AP, Guillevi L. Infliximab in the treatment of posterior uveitis in Behcet’s disease: long term follow up in four patients. Presse Med. Jul 23 2005;34(13):916–918.
   PubMed Web of Science ®Google Scholar
• Lopez-Gonzalez R, Loza E, Jover JA, et al. Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study. Scand J Rheumatol. Jan-Feb 2009;38(1):58–62.
   Google Scholar
• Mansour AM. Infliximab treatment of posterior uveitis. Ophthalmology. Jan 2004;111(1):197–198; author reply 198.
   Google Scholar
• Menghini M, Frimmel SA, Windisch R, Meier FM. Efficacy of infliximab therapy in two patients with sympathetic ophthalmia. Klin Monbl Augenheilkd. Apr 2011;228(4):362–363.
   Google Scholar
• Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology. Feb 2004;111(2):352–356.
   Google Scholar
• Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. Feb 2006;113(2):308–314.
   Google Scholar
• Richards JC, Tay-Kearney ML, Murray K, Manners P. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol. Oct 2005;33(5):461–468.
   Google Scholar
• Sharma SM, Ramanan AV, Riley P, Dick AD. Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease. Ann Rheum Dis. Jun 2007;66(6):840–841.
   Google Scholar
• Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. Feb 15 2005;53(1):18–23.
   Google Scholar
• Sobrin L, Kim EC, Christen W, Papadaki T, Letko E, Foster CS. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol. Jul 2007;125(7):895–900.
   Google Scholar
• Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behcet disease. Am J Ophthalmol. Dec 2008;146(6):845–850 e841.
   PubMed Web of Science ®Google Scholar
• Tognon S, Graziani G, Marcolongo R. Anti-TNF-alpha therapy in seven patients with Behcet’s uveitis: advantages and controversial aspects. Ann N Y Acad Sci. Sep 2007;1110:474–484.
   PubMed Web of Science ®Google Scholar
• Wang Y, Gaudio PA. Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome. Ocul Immunol Inflamm. Jul-Aug 2008;16(4):167–171.
   Google Scholar
• Wechsler B, Sable-Fourtassou R, Bodaghi B, et al. Infliximab in refractory uveitis due to Behcet’s disease. Clin Exp Rheumatol. Jul-Aug 2004;22(4 Suppl 34):S14–S16.
   PubMed Web of Science ®Google Scholar
• Katsiari CG, Theodossiadis PG, Kaklamanis PG, Markomichelakis NN, Sfikakis PP. Successful long-term treatment of refractory Adamantiades-Behcet’s disease (ABD) with infliximab: report of two patients. Adv Exp Med Biol. 2003;528:551–555.
   PubMed Web of Science ®Google Scholar
• Tynjala P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis. Apr 2007;66(4):548–550.
   PubMed Web of Science ®Google Scholar
• Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001;45(3):252–257.
   Google Scholar
• Galor A, Perez VL, Hammel P, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology. Dec 2006;113(12):2317–2323.
   PubMed Web of Science ®Google Scholar
• Saurenmann RK, Levin AV, Feldman BM, et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. Arthritis Rheum. Feb 2007;56(2):647–657.
   Google Scholar
• Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease. Br J Ophthalmol. Mar 2010;94(3):284–288.
   PubMed Web of Science ®Google Scholar
• Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford). Aug 2005;44(8):1008–1011.
   Google Scholar
• Reiff A. Long-term outcome of etanercept therapy in children with treatment-refractory uveitis. Arthritis Rheum. Jul 2003;48(7):2079–2080.
   Google Scholar
• Reiff A, Takei S, Sadeghi S, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum. Jun 2001;44(6):1411–1415.
   PubMed Web of Science ®Google Scholar
• Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol. Apr 2003;121(4):437–440.
   PubMedGoogle Scholar
• Cordero-Coma M, Salom D, Diaz-Llopis M, Lopez-Prats MJ, Calleja S. Golimumab for uveitis. Ophthalmology. Sep 2011;118(9):1892 e1893–e1894.
   Google Scholar
• Androudi S, Tsironi E, Kalogeropoulos C, Theodoridou A, Brazitikos P. Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology. Aug 2010;117(8):1612–1616.
   PubMed Web of Science ®Google Scholar
• Farvardin M, Afarid M, Mehryar M, Hosseini H. Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina. Oct 2010;30(9):1530–1535.
   Google Scholar
• Pato E, Munoz-Fernandez S, Francisco F, et al. Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis. Semin Arthritis Rheum. Feb 2011;40(4):314–323.
   Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. May 17 2006;295(19):2275–2285.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Baumgartner SW, Weisman MH, Liu T, White B, Peloso P. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis. Mar 2006;65(3):379–384.
   Google Scholar
• Jacobsson LT, Turesson C, Nilsson JA, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis. May 2007;66(5):670–675.
   Google Scholar
• Setoguchi S, Solomon DH, Weinblatt ME, et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum. Sep 2006;54(9):2757–2764.
   Google Scholar
• Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. Sep 2007;56(9):2886–2895.
   Google Scholar
• Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ. 2009;339:b2480.
   Google Scholar
• D’Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. Feb 2011;106(2):199–212; quiz 213.
   Google Scholar
• BenEzra D, Forrester JV, Nussenblatt RB, et al. Uveitis Scoring System. Berlin: Springer Verlag;1991:4–5.
   Google Scholar
• Hogan MJ, Kimura SJ, Thygeson P. Signs and symptoms of uveitis. Am J lm- Ophthalmol. 1959;47:155–170.
   PubMed Web of Science ®Google Scholar